Clinical Research Management Shared Resource

Druker, Brian J.

Abstract

The Clinical Research Management Shared Resource (CRM) supports OHSU Knight Cancer Institute investigators in conducting translational, clinical and epidemiological research aimed at improving the lives of people and families with cancer by applying innovative strategies for cancer prevention, cancer treatment, and support of cancer survivors. The CRM provides training for new investigators, fellows, research nurses and clinical trial staff in the conduct of clinical trials. The CRM facilitates innovative and translational investigator-initiated Pilot/Phase I and small Phase II institutional protocols as part of Protocol Specific Research Support. This Shared Resource assists investigators in the preparation, conduct, and reporting of local, investigator-initiated studies. Prior to study initiation, the CRM offers investigators budget development and negotiation services as well as ongoing study account management. During conduct of a trial. Cancer Institute nurse researchers and experienced study coordinators use a team approach to provide investigators with all aspects of study coordination including safety monitoring and reporting. The CRM provides personnel management and oversight of research nurses and study coordinators.

Public Health Relevance

The Clinical Research Management Shared Resource (CRM) supports OHSU Knight Cancer Institute investigators in conducting translational, clinical and epidemiological research aimed at improving the lives of people and families with cancer by applying innovative strategies for cancer prevention, cancer treatment, and support of cancer survivors.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Center Core Grants (P30)
• Project #: 5P30CA069533-17
• Application #: 8712384
• Study Section: Subcommittee B - Comprehensiveness (NCI)
• Budget Start: 2014-07-01
• Budget End: 2015-06-30
• Support Year: 17
• Fiscal Year: 2014

Institution

• Name: Oregon Health and Science University
• City: Portland
• State: OR
• Country: United States
• Zip Code: 97239

Publications

Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387

Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27

Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259

Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662

Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531

Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815

Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33

Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419

Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828